Molecular phenotypes of DCIS predict overall and invasive recurrence

Annals of Oncology

Volumn 26, Issue 5, 2015, Pages 1019-1025

  Williams, K E ^a   Barnes, N L P ^a   Cramer, A ^b   Johnson, R ^a   Cheema, K ^a   Morris, J ^a   Howe, M ^a   Bundred, Nigel J ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

DCIS; Luminal A; Molecular phenotype; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PHENOTYPE; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR VOLUME; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMISTRY; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ENGLAND; KAPLAN MEIER METHOD; MIDDLE AGED; MOLECULAR DIAGNOSIS; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; ENGLAND; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84929072738     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv062     Document Type: Article

References (30)

1. Page DL, Dupont WD, Rogers LW et al. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995; 76: 1197-1200.
2. Collins LC, Tamimi RM, Baer HJ et al. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer 2005; 103: 1778-1784.
3. Eusebi V, Feudale E, Foschini MP et al. Long-term follow-up of in situ carcinoma of the breast. Semin Diagn Pathol 1994; 11: 223-235.
4. Fisher B, Dignam J, Wolmark N et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 1998; 16: 441-452.
5. Julien JP, Bijker N, Fentiman IS et al. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000; 355: 528-533.
6. Provenzano E, Hopper JL, Giles GG et al. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 2003; 39: 622-630.
7. Allred DC, Anderson SJ, Paik S et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol 2012; 30: 1268-1273.
8. Baxter NN, Virnig BA, Durham SB et al. Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 2004; 96: 443-448.
9. Dodwell D, Clements K, Lawrence G et al. Radiotherapy following breastconserving surgery for screen-detected ductal carcinoma in situ: indications and utilisation in the UK. Interim findings from the Sloane Project. Br J Cancer 2007; 97: 725-729.
10. Wapnir IL, Dignam JJ, Fisher B et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011; 103: 478-488.
11. Cuzick J, Sestak I, Pinder SE et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2010; 12: 21-29.
12. Ringberg A, Anagnostaki L, Anderson H et al. Cell biological factors in ductal carcinoma in situ (DCIS) of the breast-relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer 2001; 37: 1514-1522.
13. Kerlikowske K, Molinaro AM, Gauthier ML et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010; 102: 627-637.
14. Kuerer HM, Buzdar AU, Mittendorf EA et al. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 2011; 117: 39-47.
15. Lari SA, Kuerer HM. Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. J Cancer 2011; 2: 232-261.
16. Cornfield DB, Palazzo JP, Schwartz GF et al. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer 2004; 100: 2317-2327.
17. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
18. Kwan ML, Kushi LH, Weltzien E et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009; 11: R31.
19. Tamimi RM, Baer HJ, Marotti J et al. Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 2008; 10: R67.
20. Boland GP, Butt IS, Prasad R et al. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004; 90: 423-429.
21. NHSBSP. Pathology reporting of breast disease. NHSBSP Publication No. 58, 2005.
22. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-750.
23. Lazzeroni M, Guerrieri-Gonzaga A, Botteri E et al. Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. Br J Cancer 2013; 108: 1593-1601.
24. Solin L, Gray R, Baehner FL, Butler S et al. A prospective validation study of the DCIS score from ECOG E5194. Cancer Res 2011; 71: 41.
25. Chan KC, Knox WF, Sinha G et al. Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ. Cancer 2001; 91: 9-16.
26. Bundred NJ, Cramer A, Morris J et al. Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial. Clin Cancer Res 2010; 16: 1605-1612.
27. Vincent-Salomon A, Lucchesi C, Gruel N et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 2008; 14: 1956-1965.
28. Clark SE, Warwick J, Carpenter R et al. Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer 2011; 104: 120-127.
29. Bijker N, Peterse JL, Duchateau L et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001; 19: 2263-2271.
30. Porter D, Lahti-Domenici J, Keshaviah A et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 2003; 1: 362-375.